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transplant; Group 2 consisted of patients with ESRD who underwent
RN, with or without subsequent transplant. Dominant tumor size and
histopathologic characteristics, recurrence and survival outcomes were
compared between groups. Chi-square and Mann-Whitney U tests were
used to compare categorical and continuous baseline and
histopathologic characteristics, respectively. Univariate analysis and
log rank test were used to compare RCC recurrence rates between
groups after RN.
RESULTS: We identified 28 RN in 24 patients in group 1 and 70
RN in 61 patients in group 2. Median time from transplant to SRM
radiologic diagnosis in group 1 was 87 months. Median time from
radiologic SRM diagnosis to RN was 3 and 4 months for group 1 and 2,
respectively. Baseline demographic, clinical and histopathologic fea-
tures of both groups are depicted in Table 1. Demographic character-
istics were similar between groups. There were no statistically
significant differences between pathologic dominant mass size, histo-
logic subtype breakdown, grade or stage between the groups. Median
follow-up after RN was 40 and 43 months for groups 1 and 2,
respectively. Univariate analysis did not reveal a statistically
significant difference in recurrence-free survival between the groups
(P[0.9). Two and 8 patients died in groups 1 and 2, respectively.
One patient died of RCC and was from group 1.
CONCLUSIONS: Patients undergoing RN before or after
transplant with malignant SRM have similar clinicopathologic charac-
teristics and recurrence-free survival outcomes. Our results suggest
that patients with ESRD and SRM need not delay transplant and AS
may be a good first line option for many.
Source of Funding: None
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INTRODUCTION AND OBJECTIVES: Primary small cell car-
cinoma (PSCC) of the kidney represents a rare disease entity. There is
little data about the characteristics, optimal therapies, and survival
associated with this malignancy. We examined the largest cohort of
patients to date with PSCC of the kidney in order to better characterize
the disease.
METHODS: We utilized the National Cancer Database (NCDB)
to identify patients with histology-confirmed primary small cell
carcinoma of the kidney with no history of other malignancies
between 2004 and 2015. Three patients with unknown treatment
regimens and the one patient who received radiotherapy alone were
excluded from analysis. Adjusted Cox proportional hazards regression
was utilized to assess overall patient survival. Kaplan-Meier analysis
was used to estimate median survival time
RESULTS: We identified 121 patients with PSCC of the kidney
who met inclusion criteria. The patients with treatment had a median
overall survival time of 10.28 months. 23.1% of patients had no treat-
ment, with a median survival of 1.64 months. We found no gender
predominance in disease prevalence (Table 1). Female gender, how-
ever, was associated with increased mortality when compared to males
(p[0.043, OR 2.02). Patients treated at academic facilities had signif-
icantly improved survival (p[0.015, OR 0.39), while those managed at
integrated cancer centers (p[0.046, OR 2.80) fared worse compared
to those treated at comprehensive community cancer programs.
Metastasis upon presentation, found in 47.1% of patients, was asso-
ciated with an increased risk of mortality (p[0.043, OR 2.23), as was
lymph node involvement (cN1: p[0.05, OR 2.46). Surgery alone was
performed in 26.4% of patients with a median survival of 9.00 months
(Figure 1) compared to 13.50 months in the 18.2% of patients who
received surgery with adjuvant chemotherapy (p[0.37).
CONCLUSIONS: PSCC of the kidney is a rare and very
aggressive malignancy with a median survival less than one year.
In the largest cohort of such patients to date, we found that multi-
modal treatment approaches improve survival. Surgery alone is
associated with a lower median survival time, despite being the
most frequently employed treatment modality. Future studies
should focus on correlating clinical tumor staging with specific
treatment modalities to best optimize management for individual
patients.
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INTRODUCTION AND OBJECTIVES: Shared decision making
is important for patients who are considering treatment of small renal
masses (SRM). The purpose of this study was to compare patient’s
opinions with surgeon perspectives regarding the use of pre-treatment
SRM biopsy.
METHODS: A 5 question survey was given to 100 consecutive
patients with SRM before and after treatment discussion. The patient
survey contains questions about anxiety level (visual analog scale) and
whether patients believed biopsy would be helpful make decision about
treatment. In addition to patient survey, a 10 question surgeon survey
was linked to email sent to active members of the Society of Urologic
Oncology. Respondents were grouped based on date of completion of
training, type of practice, and geographic location.
RESULTS: A total of 100 consecutive patients completed a
survey prior to discussion of SRM treatment. Pre-discussion anxiety
was high with 46% of patients responding that SRM diagnosis was
“among most stressful moments in life” When patients were asked
“Would knowing whether or not there is cancer in your renal mass
help you to make a decision about treatment?”, 81% answered yes.
When asked if they would consider biopsy, 84% answered yes. After
renal mass counseling, only 46% of patients answered yes to “did
you decide to have a biopsy?”. A total of 42/100 patients
subsequently received biopsy.
Of 717 surgeons who were emailed, 111 (15.5%) completed the
online survey. Practice type included: Academic (76%), private (18%)
and military/government (6%). The median year when training was
completed was 2009 (IQR 2000-2015) and 62% of respondents
evaluating 5 SRM/month. When asked how often biopsy is recom-
mended for SRM, 60% recommend biopsy<25% of SRM patients, 20%
recommend biopsy for half of SRM patients and 20% recommend bi-
opsy greater for than 75% of SRM.
Training year and type of practice were not associated with how
frequently biopsy was recommended (p[0.27, 0.17). Common re-
sponses for the advantage of using biopsy to evaluate SRM included:
To identify benign tumors and avoid treatment (49%), to risk stratify
renal cancer patients prior to treatment (21%), and to improve informed
consent prior to treatment (14%). The most common response for why
biopsy was not recommended is that it would not change manage-
ment (86%).
CONCLUSIONS: Before counseling, most SRM patients favor
biopsy. After treatment discussion, less than half of patients favored
biopsy with 42% subsequently receiving biopsy. Practice patterns
remain variable among surgeons, with 40% of respondents recom-
mending biopsy for at least half of SRM evaluated.
Source of Funding: None
MP19-14
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INTRODUCTION AND OBJECTIVES: Kidney cancer surveil-
lance following nephrectomy is predominantly based on imaging and
laboratory evaluation, rather than physical exam. Despite this, patients
make substantial sacrifices to attend in-person follow-up visits. We
sought to characterize the burden of kidney cancer surveillance in a
low-resource population, with an aim to identify opportunities for
telehealth implementation.
METHODS: We performed a retrospective review of patients
who underwent partial or radical nephrectomy between November 2016
and May 2018 at an academic medical center with a large, rural referral
base. We reviewed patient demographic characteristics including age,
travel distance to hospital, Center for Medicare & Medicaid Services
designation of home ZIP code as a Low-Income Area (LIA) or Health
Professional Shortage Area (HPSA), and employment status. Follow-
up visits were reviewed for intended and obtained imaging and
laboratory studies, as well as new physical exam findings.
RESULTS: We identified 156 patients who attended 234 follow-
up visits at mean 2.4 months (SD 2.9 months) following partial or radical
nephrectomy. Patients’ home ZIP codes were designated as LIA or
HPSA in 93 (59.6%) cases. Fifty-three patients (34%) were employed
at time of follow-up. One-way travel was mean 194 miles (SD 438
miles) for each visit. When intended, laboratory or imaging studies
were not obtained ahead of follow-up visits in 34 of 196 cases (17%).
New physical exam findings that altered management were identified
in 27 visits (11%), though 17 of these occurrences (86%) were at the
first post-op visit. Based on the absence of new physical exam
findings or procedures performed, 201 (86%) visits were amenable
to a telehealth encounter rather than in-person appointment.
CONCLUSIONS: Patients living in LIAs and HPSAs are asked
to travel long distances to attend kidney cancer surveillance visits, often
(86%) to review data that could have been obtained remotely. Neces-
sary imaging or laboratory studies are frequently (17%) not obtained
ahead of appointments, further diminishing their value. Kidney cancer
surveillance may offer a promising opportunity for telehealth imple-
mentation within urology.
Source of Funding: This work was supported in part by the
Urology Care Foundation Residency Research Award and
Russell Scott, Jr., MD Urology Research Fund.
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INTRODUCTION AND OBJECTIVES: The 2017 AUA Guide-
lines for localized renal cell cancer (RCC) recommend genetic
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